Comparing GLP-1 Agonists: A Comprehensive Review of Their Efficacy and Safety Profiles

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 receptor agonists effectively improve glycemic control and promote weight loss, with semaglutide showing superior efficacy. They also offer cardiovascular benefits and have generally well-tolerated safety profiles.

# Comparing GLP-1 Agonists: Efficacy and Safety

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a powerful class of medications primarily used in the management of type 2 diabetes mellitus (T2DM) and obesity. These agents mimic the action of the endogenous incretin hormone GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. As the number of GLP-1 agonists available on the market grows, understanding their comparative efficacy and safety profiles is essential for clinicians and patients alike. This article explores key GLP-1 receptor agonists, reviewing their mechanisms, dosing protocols, efficacy data, and safety considerations.

---

Overview of GLP-1 Receptor Agonists

GLP-1 receptor agonists are injectable or oral medications that improve glycemic control and have demonstrated cardiovascular benefits in certain populations. Commonly prescribed agents include:

  • Exenatide (Byetta, Bydureon)
  • Liraglutide (Victoza, Saxenda)
  • Dulaglutide (Trulicity)
  • Semaglutide (Ozempic, Rybelsus)
  • Lixisenatide (Adlyxin)
  • Albiglutide (Tanzeum) — note: discontinued in some markets

    • Each of these agents differs in molecular structure, dosing frequency, and formulation, which can influence patient adherence and outcomes.

    ---

    Mechanism of Action

    GLP-1 agonists bind to GLP-1 receptors on pancreatic beta cells, stimulating insulin secretion in a glucose-dependent manner—meaning they primarily act when blood glucose levels are elevated. They also suppress inappropriate glucagon secretion from alpha cells, reduce appetite by acting on the hypothalamus, and slow gastric emptying, which moderates postprandial glucose spikes.

    ---

    Comparative Efficacy

    Glycemic Control

    Most GLP-1 receptor agonists reduce HbA1c by approximately 1.0% to 1.5%, a clinically significant improvement in glycemic management.

  • Semaglutide has shown superior efficacy in glycemic reduction compared to other GLP-1 agonists in head-to-head trials. For example, the SUSTAIN trials demonstrated HbA1c reductions up to 1.8%.
  • Dulaglutide and liraglutide typically reduce HbA1c by about 1.2-1.5%.
  • Exenatide usually achieves slightly less reduction, around 0.9-1.2%.

    • Weight Loss

    GLP-1 agonists are associated with weight loss, which benefits many patients with T2DM and obesity.

  • Semaglutide again leads in this category, with weight reductions up to 15% in obesity trials (e.g., STEP studies).
  • Liraglutide is FDA-approved for weight management (Saxenda) and produces moderate weight loss (~5-7%).
  • Dulaglutide and exenatide have more modest effects on weight, generally 2-4%.

    • Cardiovascular Outcomes

    Several GLP-1 agonists have demonstrated cardiovascular benefits in patients with T2DM and established cardiovascular disease:

  • Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND) showed significant reductions in major adverse cardiovascular events (MACE).
  • Exenatide and lixisenatide have less robust or neutral cardiovascular data.

    • ---

    Safety Profiles and Side Effects

    Common Side Effects

    GLP-1 agonists are generally well tolerated. The most common adverse effects include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal discomfort

    • These gastrointestinal symptoms often diminish over time and can be mitigated by starting at a low dose and titrating gradually.

    Hypoglycemia Risk

    When used as monotherapy or with agents other than sulfonylureas or insulin, GLP-1 agonists have a low risk of hypoglycemia due to their glucose-dependent mechanism.

    Pancreatitis and Gallbladder Disease

    There have been post-marketing reports of pancreatitis and gallbladder disease, but large clinical trials have not established a definitive causal relationship. Patients with a history of pancreatitis should use these agents cautiously.

    Medullary Thyroid Carcinoma (MTC)

    Animal studies raised concerns about C-cell tumors, but this has not been demonstrated in humans. Nonetheless, GLP-1 agonists are contraindicated in patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2.

    ---